- Home
- MODD vs CLGN Comparison
MODD vs CLGN Comparison
Compare MODD & CLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MODD
- CLGN
- Stock Information
- Founded
- MODD 1998
- CLGN 2004
- Country
- MODD United States
- CLGN Israel
- Employees
- MODD N/A
- CLGN N/A
- Industry
- MODD Industrial Specialties
- CLGN Industrial Specialties
- Sector
- MODD Health Care
- CLGN Health Care
- Exchange
- MODD Nasdaq
- CLGN Nasdaq
- Market Cap
- MODD 46.3M
- CLGN 22.1M
- IPO Year
- MODD N/A
- CLGN N/A
- Fundamental
- Price
- MODD $0.83
- CLGN $3.11
- Analyst Decision
- MODD
- CLGN Strong Buy
- Analyst Count
- MODD 0
- CLGN 2
- Target Price
- MODD N/A
- CLGN $11.50
- AVG Volume (30 Days)
- MODD 78.5K
- CLGN 165.3K
- Earning Date
- MODD 06-20-2025
- CLGN 05-28-2025
- Dividend Yield
- MODD N/A
- CLGN N/A
- EPS Growth
- MODD N/A
- CLGN N/A
- EPS
- MODD N/A
- CLGN N/A
- Revenue
- MODD N/A
- CLGN $2,472,000.00
- Revenue This Year
- MODD N/A
- CLGN $2,177.67
- Revenue Next Year
- MODD N/A
- CLGN $56.52
- P/E Ratio
- MODD N/A
- CLGN N/A
- Revenue Growth
- MODD N/A
- CLGN N/A
- 52 Week Low
- MODD $0.68
- CLGN $1.55
- 52 Week High
- MODD $2.65
- CLGN $5.63
- Technical
- Relative Strength Index (RSI)
- MODD 36.37
- CLGN 58.91
- Support Level
- MODD $0.75
- CLGN $3.00
- Resistance Level
- MODD $0.90
- CLGN $4.98
- Average True Range (ATR)
- MODD 0.07
- CLGN 0.40
- MACD
- MODD -0.01
- CLGN 0.22
- Stochastic Oscillator
- MODD 29.09
- CLGN 45.48
About MODD Modular Medical Inc.
Modular Medical Inc is a development stage medical device company which focuses on the design, development, and commercialization of insulin pumps using modernized technology to increase pump adoption in the diabetes marketplace. The company's products seek to serve both the type 1 and the rapidly growing, especially in terms of device adoption, type 2 diabetes markets.
About CLGN CollPlant Biotechnologies Ltd
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives key revenue, Canada, Europe and Other, and Israel.